You are here:

Archived: olodaterol 2.5 microgram solution for inhalation (Striverdi® Respimat®)

Advice

following a full submission:

olodaterol (Striverdi® Respimat®) is not recommended for use within NHS Scotland.

Indication under review: maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease.

In two 48-week studies there was no significant difference between olodaterol 5 microgram and another long acting beta2 agonist for the primary endpoints of trough forced expiratory volume in 1 second (FEV1) and FEV1 area under curve (0 to 3 hours) at week 24.

The submitting company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.

The licence holder has indicated their intention to resubmit.

Drug Details

Drug Name: olodaterol 2.5 microgram solution for inhalation (Striverdi® Respimat®)
SMC Drug ID: 974/14
Manufacturer: Boehringer Ingelheim Ltd
Indication: maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease.
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 11 August 2014

Current Advice

Resubmission 12 January 2015

Back